Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Johnson & Johnson (NYSE:JNJ) recently announced a 4.8% increase in its quarterly dividend and released positive Phase 3 ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Psoriasis shows on the skin, but it's a disease which goes a lot deeper and is linked to serious health problems. In recent years, newer targeted drugs are making a difference.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

As of December 31, 2024, Can-Fite had cash and cash equivalents and short term deposits of $7.88 million as compared to $8.90 million as of December 31, 2023. The decrease in cash during the year ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.